Notice Pursuant to the National Cooperative Research and Production Act of 1993-Biopharmaceutical Manufacturing Preparedness Consortium, 52097 [2024-13621]
Download as PDF
Federal Register / Vol. 89, No. 120 / Friday, June 21, 2024 / Notices
DEPARTMENT OF JUSTICE
Antitrust Division
ddrumheller on DSK120RN23PROD with NOTICES1
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Biopharmaceutical
Manufacturing Preparedness
Consortium
Notice is hereby given that, on April
12, 2024, pursuant to section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Biopharmaceutical
Manufacturing Preparedness
Consortium (‘‘BIOMAP–
CONSORTIUM’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, A-line, Inc., Signal Hill,
CA; API Innovation Center, St. Louis,
MO; AVS Bio, Norwich, CT; Advanced
Concept Innovations, Lakeland, FL;
Afton Scientific, Charlottesville, VA;
Alchem Laboratories Corp., Alachua,
FL; AmerStem, Inc., Camarillo, CA;
American Medicines Company, PBC,
Davisville, WV; American Type Culture
Collection, Manassas, VA; Amyris, Inc.,
Emeryville, CA; AntoXa Corp., Toronto,
CANADA; Apertus Pharmaceuticals
LLC, Ballwin, MO; Argonaut
Manufacturing Services, Inc., Carlsbad,
CA; Asha Therapeutics LLC, Tampa, FL;
Attogene Corp., Austin, TX; BASF
Corp., Florham Park, NJ; BCG Federal
Corp., Washington, DC; BDO Public
Sector LLC, McLean, VA; Batavia
Biosciences, Inc., Woburn, MA; Benuvia
Operations LLC, Round Rock, TX;
Bionova Scientific LLC, Fremont, CA;
Biosortia Pharmaceuticals, Inc., Dublin,
OH; Black Mesa Technology, Inc.,
Bedford, MA; Blu Zone Bioscience &
Supply Chain Solutions, LLC, Frederick,
MD; Bracane Company, Inc., Plano, TX;
CGCN, Washington, DC; CMC
Pharmaceuticals, Inc., Solon, OH; Capra
Biosciences, Inc., Manassas, VA;
ChromaTan, Inc., Lower Gwynedd, PA;
Concept to Market LLC, Monrovia, MD;
Cornerstone Chemical Company,
Metairie, LA; Corning, Inc., Corning,
NY; CuriRx, Inc., Wilmington, MA;
DEKA Research & Development Corp.,
Manchester, NH; DMC Biotechnologies,
Inc., Boulder, CO; Dyadic International,
Inc., Jupiter, FL; EriVan Bio, Alachua,
FL; EverGlade Consulting LLC, Houston,
TX; Evimero, Tuscaloosa, AL; FUJIFILM
Diosynth Biotechnologies USA, Inc.,
Morrisville, NC; Fisher BioServices,
VerDate Sep<11>2014
17:46 Jun 20, 2024
Jkt 262001
Inc., Rockville, MD; Foamtec
International LLC, Waco, TX;
Fraunhofer USA, Plymouth, MI; HDT
Bio Corp., Seattle, WA; HERMES, LLC,
Wilmington, NC; Health Blockchain
Convergence, Inc., Tysons Corner, VA;
INTACT SOLUTIONS LLC, New
Milford, CT; InflaRx GmbH, Jena,
GERMANY; Interbiome Partners LLC,
Rockville, MD; Jubilant HollisterStier
CMO, Spokane, WA; Kemp Proteins,
Frederick, MD; LaCire LLC, Alexandria,
VA; Latham BioPharm Group, Elkridge,
MD; MalarVx, Inc., Seattle, WA;
Mallinckrodt Specialty Generics dba
SpecGx LLC, Webster Groves, MO;
Manus Bio, Inc., Waltham, MA; Medical
Countermeasures Coalition,
Washington, DC; Meissner Filtration
Products, Inc., Camarillo, CA; Michael
Best Strategies, Washington, DC;
MilliporeSigma, Burlington, MA;
Nature’s Toolbox, Inc., Rio Rancho, NM;
New Horizon Biotech, Inc., Nazareth,
PA; NewAge Industries, Inc.,
Southampton, PA; Nipro
PharmaPackaging Americas Corp.,
Millville, NJ; On Demand
Pharmaceuticals, Inc., Rockville, MD;
PPD Development, L.P., Wilmington,
NC; Par Sterile Product LLC, Rochester,
MI; PharmaJet, Golden, CO; Phlow
Corp., Richmond, VA; Prestige
Ameritech, Ltd., North Richland Hills,
TX; ProQuality Network LLC, Dorado,
PUERTO RICO; Proteios Technology,
Inc., Issaquah, WA; Quantum Four Labs
LLC, Arcadia, CA; SANARIA, Inc.,
Rockville, MD; SCHOTT Pharma USA,
Inc., Lebanon, PA; SK Pharmteco,
Rancho Cordova, CA; STERIS Corp.,
Mentor, OH; Scorpius
Biomanufacturing, Inc., San Antonio,
TX; Sentio BioSciences LLC, Maryland
Heights, MO; Sepragen Corp., Union
City, CA; Shabas Solutions LLC, Fairfax,
VA; Societal CDMO Inc., Gainesville,
GA; Sotera Health Company, Broadview
Heights, OH; Southwest Research
Institute, San Antonio, TX; Strategic
Marketing Innovations, Washington, DC;
TEGA Therapeutics, Inc., San Diego,
CA; TFF Pharmaceuticals, Inc., Fort
Worth, TX; Tenagrity Solutions LLC,
Fairfax, VA; Texas A&M Engineering
Experiment Station, Bryan, TX; Texas
Biomedical Research Institute, San
Antonio, TX; Thaddeus Medical
Systems, Inc., Rochester, MN; The
United States Pharmacopeial
Convention, Inc., Rockville, MD; Third
Pole, Inc., Waltham, MA; Tonix
Pharmaceuticals Holding Corp.,
Chatham, NJ; TriLink BioTechnologies
LLC, San Diego, CA; US Specialty
Formulations, Allentown, PA;
University of Delaware, Newark, DE;
Vaxess Technologies, Inc., Cambridge,
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
52097
MA; Wheeler Bio, Inc., Oklahoma City,
OK; and Zalgen Labs LLC, Frederick,
MD, have been added as parties to this
venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and the BIOMAP–
CONSORTIUM intends to file additional
written notifications disclosing all
changes in membership.
On January 5, 2024, the BIOMAP–
CONSORTIUM filed its original
notification pursuant to section 6(a) of
the Act. The Department of Justice
published a notice in the Federal
Register pursuant to section 6(b) of the
Act on April 16, 2024 (89 FR 26923).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
[FR Doc. 2024–13621 Filed 6–20–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Information Warfare
Research Project Consortium
Notice is hereby given that, on April
3, 2024, pursuant to section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Information Warfare
Research Project Consortium (‘‘IWRP’’)
has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, 10x National Security LLC,
Aldie, VA; Accrete AI Government LLC,
New York, NY; BlueSky Mast, Inc.,
Largo, FL; CALIBRE Systems, Inc.,
Alexandria, VA; cBEYONData LLC,
Arlington, VA; Comtech Satellite
Network Technologies, Inc., Chandler,
AZ; Cybrex LLC, Norfolk, VA; DOMA
Technologies LLC, Virginia Beach, VA;
Echodyne Corp., Kirkland, WA; Ellis &
Watts Global Industries, Inc., Batavia,
OH; FishEye Software, Inc., Maynard,
MA; Goldbelt Security LLC,
Chesapeake, VA; M.C. Dean, Inc.,
Tysons, VA; Management Services
Group, Inc., Virginia Beach, VA;
mLogica LLC, Las Vegas, NV; Sciumo,
Inc., Odenton, MD; Sextant
Technologies LLC, Washington, DC;
E:\FR\FM\21JNN1.SGM
21JNN1
Agencies
[Federal Register Volume 89, Number 120 (Friday, June 21, 2024)]
[Notices]
[Page 52097]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-13621]
[[Page 52097]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Biopharmaceutical Manufacturing Preparedness
Consortium
Notice is hereby given that, on April 12, 2024, pursuant to section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Biopharmaceutical Manufacturing
Preparedness Consortium (``BIOMAP-CONSORTIUM'') has filed written
notifications simultaneously with the Attorney General and the Federal
Trade Commission disclosing changes in its membership. The
notifications were filed for the purpose of extending the Act's
provisions limiting the recovery of antitrust plaintiffs to actual
damages under specified circumstances.
Specifically, A-line, Inc., Signal Hill, CA; API Innovation Center,
St. Louis, MO; AVS Bio, Norwich, CT; Advanced Concept Innovations,
Lakeland, FL; Afton Scientific, Charlottesville, VA; Alchem
Laboratories Corp., Alachua, FL; AmerStem, Inc., Camarillo, CA;
American Medicines Company, PBC, Davisville, WV; American Type Culture
Collection, Manassas, VA; Amyris, Inc., Emeryville, CA; AntoXa Corp.,
Toronto, CANADA; Apertus Pharmaceuticals LLC, Ballwin, MO; Argonaut
Manufacturing Services, Inc., Carlsbad, CA; Asha Therapeutics LLC,
Tampa, FL; Attogene Corp., Austin, TX; BASF Corp., Florham Park, NJ;
BCG Federal Corp., Washington, DC; BDO Public Sector LLC, McLean, VA;
Batavia Biosciences, Inc., Woburn, MA; Benuvia Operations LLC, Round
Rock, TX; Bionova Scientific LLC, Fremont, CA; Biosortia
Pharmaceuticals, Inc., Dublin, OH; Black Mesa Technology, Inc.,
Bedford, MA; Blu Zone Bioscience & Supply Chain Solutions, LLC,
Frederick, MD; Bracane Company, Inc., Plano, TX; CGCN, Washington, DC;
CMC Pharmaceuticals, Inc., Solon, OH; Capra Biosciences, Inc.,
Manassas, VA; ChromaTan, Inc., Lower Gwynedd, PA; Concept to Market
LLC, Monrovia, MD; Cornerstone Chemical Company, Metairie, LA; Corning,
Inc., Corning, NY; CuriRx, Inc., Wilmington, MA; DEKA Research &
Development Corp., Manchester, NH; DMC Biotechnologies, Inc., Boulder,
CO; Dyadic International, Inc., Jupiter, FL; EriVan Bio, Alachua, FL;
EverGlade Consulting LLC, Houston, TX; Evimero, Tuscaloosa, AL;
FUJIFILM Diosynth Biotechnologies USA, Inc., Morrisville, NC; Fisher
BioServices, Inc., Rockville, MD; Foamtec International LLC, Waco, TX;
Fraunhofer USA, Plymouth, MI; HDT Bio Corp., Seattle, WA; HERMES, LLC,
Wilmington, NC; Health Blockchain Convergence, Inc., Tysons Corner, VA;
INTACT SOLUTIONS LLC, New Milford, CT; InflaRx GmbH, Jena, GERMANY;
Interbiome Partners LLC, Rockville, MD; Jubilant HollisterStier CMO,
Spokane, WA; Kemp Proteins, Frederick, MD; LaCire LLC, Alexandria, VA;
Latham BioPharm Group, Elkridge, MD; MalarVx, Inc., Seattle, WA;
Mallinckrodt Specialty Generics dba SpecGx LLC, Webster Groves, MO;
Manus Bio, Inc., Waltham, MA; Medical Countermeasures Coalition,
Washington, DC; Meissner Filtration Products, Inc., Camarillo, CA;
Michael Best Strategies, Washington, DC; MilliporeSigma, Burlington,
MA; Nature's Toolbox, Inc., Rio Rancho, NM; New Horizon Biotech, Inc.,
Nazareth, PA; NewAge Industries, Inc., Southampton, PA; Nipro
PharmaPackaging Americas Corp., Millville, NJ; On Demand
Pharmaceuticals, Inc., Rockville, MD; PPD Development, L.P.,
Wilmington, NC; Par Sterile Product LLC, Rochester, MI; PharmaJet,
Golden, CO; Phlow Corp., Richmond, VA; Prestige Ameritech, Ltd., North
Richland Hills, TX; ProQuality Network LLC, Dorado, PUERTO RICO;
Proteios Technology, Inc., Issaquah, WA; Quantum Four Labs LLC,
Arcadia, CA; SANARIA, Inc., Rockville, MD; SCHOTT Pharma USA, Inc.,
Lebanon, PA; SK Pharmteco, Rancho Cordova, CA; STERIS Corp., Mentor,
OH; Scorpius Biomanufacturing, Inc., San Antonio, TX; Sentio
BioSciences LLC, Maryland Heights, MO; Sepragen Corp., Union City, CA;
Shabas Solutions LLC, Fairfax, VA; Societal CDMO Inc., Gainesville, GA;
Sotera Health Company, Broadview Heights, OH; Southwest Research
Institute, San Antonio, TX; Strategic Marketing Innovations,
Washington, DC; TEGA Therapeutics, Inc., San Diego, CA; TFF
Pharmaceuticals, Inc., Fort Worth, TX; Tenagrity Solutions LLC,
Fairfax, VA; Texas A&M Engineering Experiment Station, Bryan, TX; Texas
Biomedical Research Institute, San Antonio, TX; Thaddeus Medical
Systems, Inc., Rochester, MN; The United States Pharmacopeial
Convention, Inc., Rockville, MD; Third Pole, Inc., Waltham, MA; Tonix
Pharmaceuticals Holding Corp., Chatham, NJ; TriLink BioTechnologies
LLC, San Diego, CA; US Specialty Formulations, Allentown, PA;
University of Delaware, Newark, DE; Vaxess Technologies, Inc.,
Cambridge, MA; Wheeler Bio, Inc., Oklahoma City, OK; and Zalgen Labs
LLC, Frederick, MD, have been added as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and the BIOMAP-CONSORTIUM intends to
file additional written notifications disclosing all changes in
membership.
On January 5, 2024, the BIOMAP-CONSORTIUM filed its original
notification pursuant to section 6(a) of the Act. The Department of
Justice published a notice in the Federal Register pursuant to section
6(b) of the Act on April 16, 2024 (89 FR 26923).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-13621 Filed 6-20-24; 8:45 am]
BILLING CODE P